Mawi DNA Technologies Announces Partnership with FUJIFILM
4.10.2021 16:00:00 EEST | Business Wire | Press release
Mawi DNA Technologies (Mawi) has signed a distribution agreement with FUJIFILM Wako Pure Chemical Corporation, a leader in the biomedical industry, to deliver Mawi’s iSWAB biosampling technologies to Japan.
“The collaboration with FUJIFILM Wako to provide iSWAB Microbiome-EL sample collection tubes for molecular testing of COVID-19 by PCR and LAMP based assay allows us to offer a valuable solution in the Japanese market,” said Atsushi Yanai, Asia Pacific Business Development at Mawi. “Being able to offer the collection without the need for an RNA Extraction step complements the WAKO Genomics product range, a valuable solution in the Japanese market and to society.”
FUJIFILM will be an authorized agent and distributor for Mawi products in Japan to detect viruses such as COVID-19.
“We are extremely grateful for the opportunity to partner with FUJIFILM, a respected organization with access to key customers in the Japanese market,” added Jerome David, VP of Sales and Marketing at Mawi. “We are confident that this initial partnership around our iSWAB-Microbiome-EL technology for extraction-less detection of SARS-CoV-2 RNA in patient samples will lead to additional opportunities for our entire portfolio of biosample collection products.”
About FUJIFILM Wako Pure Chemical Corporation
FUJIFILM Wako Pure Chemical Corporation is a comprehensive laboratory chemicals manufacturer contributing to a number of cutting-edge research fields. Over time, the company has developed and manufactured high-quality products and expanded its businesses to include specialty chemicals and clinical diagnostic reagents. For more information, visit https://www.fujifilm.com/ffwk/en.
About Mawi DNA Technologies
Mawi DNA Technologies, founded in 2013, has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Mawi’s mission is to uphold sample integrity from anywhere in the world at room temperature, enabling true sample diversity across any geography or population segment. The company’s flagship product iSWAB-DNA is the only sample collection product on the market proven to produce a high quality DNA sample with low bacterial DNA content. Mawi also supplies products for collection of RNA, microbiome, intact cells, and whole blood. At Mawi, The Future of Biosampling is Here™. For more information, visit http://www.mawidna.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005344/en/
Contact information
Media Contact:
Susan Tellem, APR, RN, BSN
310-313-3444 x1, Susan@tellemgrodypr.com
Investors:
Jerome David, VP of Sales and Marketing
510-256-5186, j.david@mawidna.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Delivers Strong Start to 2026 With $1Bn Revenue and $68M Adj. Operating Profit14.5.2026 14:30:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, today reported first quarter 2026 results. GMV reached $33.7 billion (+33% YoY), revenue $1.0 billion (+44% YoY), transaction margin dollars $389 million (+44% YoY), and adjusted operating profit $68 million, up from $3 million a year ago. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514241288/en/ "Klarna addresses the entire consumer wallet: Pay Now for everyday spending and saving, Pay Later our charge card equivalent at 0% interest for mid-size ticket spending, and POS installments (Fair Financing) for big-ticket purchases. In Q1 we executed well across all the business, driving every line of our P&L and compounding growth across our global network. Growing network. Same three products. Deeper consumer engagement.” Sebastian Siemiatkowski, CEO & Co-Founder, Klarna Q1 2026 Highlights GMV: $33.7 billion (+33% YoY); U.S. +39%, ex-U.S. +31% Revenue: $1.0 bil
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 202614.5.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of
SBC Medical Group Holdings Announces First Quarter 2026 Financial Results14.5.2026 13:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced its financial results for the three months ended March 31, 2026. First Quarter 2026 Highlights Total revenues were $43 million, representing a 9% year-over-year decrease. Net income attributable to SBC Medical Group Holdings Incorporated was $11 million, representing a 47% year-over-year decrease. Net income margin was 26% for the first quarter of 2026, representing a year-over-year decrease of 19 percentage points. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.11 for the three months ended March 31, 2026, representing a 48% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense to income from operations was $18 million, representing a
FPT Strengthens Bavarian Presence with New Munich Office, Accelerating AI Transformation14.5.2026 12:13:00 EEST | Press release
Global technology corporation FPT officially cut the ribbon on its latest office in Germany. This milestone reinforces the company's long-term commitment to delivering AI-driven services to its growing customer base across Germany and the wider European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514689341/en/ The inauguration ceremony was attended by H.E. Mr Nguyen Dac Thanh, Ambassador of Vietnam to Germany, alongside representatives from the local government, FPT executives, and key partners. Situated in one of Europe’s most dynamic technological and manufacturing hubs, the Munich office strengthens FPT’s delivery capabilities and enables faster, more scalable engagement across the region. The move underscores the company’s strategic focus on investing in key innovation hubs to meet rising demand for AI transformation and accelerate time-to-value for clients. "Our expanded presence in Munich allows us to sta
Reply Launches Model Factory, the Production Line for Creating Industrial-Grade Generative AI Models14.5.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY] announces Reply Model Factory, an industrial production line for buildingfrontier generative AI modelsgrounded in corporate knowledge and designed to power AI systems and agents aligned with each organisation’s operational context. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514524231/en/ Reply Model Factory is an industrial production line for building frontier generative AI models grounded in corporate knowledge and designed to power AI systems and agents aligned with each organisation’s operational context. AI models are often built to operate across a wide range of tasks, drawing largely on public data. Enterprises, however, rely on internal knowledge: technical standards, regulatory requirements, operating procedures, proprietary systems and domain expertise. Reply Model Factory addresses this gap by enabling organisations to train models that understand their own context and operate consist
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom